From Internal Research to External Innovation

BioCryst Pharmaceuticals (BCRX) will close its Birmingham, Alabama research facility by the end of 2026 and discontinue internal drug discovery efforts. Instead, the company plans to in-license two clinical-stage rare disease assets over the next 18 months and focus its capital on the development of navenibart and BCX17725. The decision to lower its 2026 non-GAAP operating expense guidance from USD$450M-470M to USD$420M-440M demonstrates that this move is not only about changing the research direction but also about restructuring its cost structure. By reducing the risk of long-term failure of early-stage candidates, the company is betting that the price and due diligence capabilities of external assets will drive growth.

Orladeyo Provides Resources for Strategic Shift

Orladeyo (berotralstat), a marketed product, is a once-daily oral prophylactic treatment for hereditary angioedema (HAE) that inhibits plasma kallikrein. The FDA approved the capsule formulation for adults and patients 12 years and older in December 2020, and on December 11, 2025, approved a pellet formulation for pediatric patients 2 years and older. In the second quarter of 2026, sales were USD$158.2M, and the company's annual Orladeyo sales guidance is USD$625M-645M. This cash-generating product will support the company's late-stage and in-licensing activities, but the success of subsequent assets will be crucial to reducing its reliance on a single product.

Navenibart as the Next-Generation HAE Asset

Navenibart (STAR-0215) is a long-acting monoclonal antibody that targets plasma kallikrein and is in Phase 3 development. BioCryst acquired this candidate in January 2026 through the acquisition of Astria Therapeutics and has initiated enrollment in the pivotal ALPHA-ORBIT Phase 3 trial (NCT06842823), with enrollment completed in June 2026. Top-line results from the six-month and 12-month studies, which evaluated subcutaneous administration every three and six months, are expected in the third quarter of 2027, with a U.S. regulatory filing targeted for the end of 2027. If successful, the company will have both a daily oral medication (Orladeyo) and a long-acting injectable, allowing it to build a HAE franchise that caters to different patient preferences.

BCX17725 and Licensing to Diversify Risk

BCX17725 is a Phase 1 protein therapeutic designed to inhibit skin serine protease KLK5 and correct protein dysregulation in Netherton syndrome. Part 4 of the trial, which involves up to 12 patients, is expected to generate proof-of-concept data by the end of 2026. As there are no approved targeted therapies for this indication, the clinical signal will have significant strategic value. In May 2026, BioCryst entered into an agreement with Neopharmed Gentili to transfer the European commercial rights to navenibart in exchange for an upfront payment of USD$70M, regulatory and sales milestone payments of up to USD$275M, and a royalty of 18-30% on net sales. The company will retain the U.S. rights and share the European launch costs with its partner, which will help to alleviate the financial burden of late-stage development.

Competition to Play Out in Convenience and Therapeutic Focus

The HAE market is expected to reach USD$6B by 2029, according to Intellia Therapeutics (NTLA). The current standard of care for prophylactic treatment includes Takhzyro (lanadelumab, a plasma kallikrein antibody) from Takeda Pharmaceutical (TAK) and Haegarda (C1 esterase inhibitor) from CSL. Ekterly (sebetralstat, a plasma kallikrein inhibitor) from KalVista, which was acquired by Chiesi Farmaceutici, is an oral medication for acute attacks in patients 12 years and older and was approved by the FDA on July 3, 2025. It has a different therapeutic focus than Orladeyo, which is a prophylactic treatment. NTLA-2002 from Intellia Therapeutics (NTLA) is a CRISPR-based therapy that targets KLKB1 and is in Phase 3 development. Therefore, the key for BioCryst will be to demonstrate that navenibart can replicate its efficacy and safety in a 3-6 month dosing interval and create a complementary prescribing pattern with Orladeyo.